Tempest Therapeutics annual debt-to-equity ratio
2018
2021
2022
2023
2024
2025
Tempest Therapeutics Debt-to-Equity Ratio Growth & History (TPST)
Tempest Therapeutics's debt-to-equity ratio was 1.22 for fiscal 2025.
View full Tempest Therapeutics company overviewTempest Therapeutics annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 1.22 | 0.42 | +51.98% |
| 2024 | 2024-12-31 | 0.80 | 0.03 | +4.08% |
| 2023 | 2023-12-31 | 0.77 | −0.45 | −36.79% |
| 2022 | 2022-12-31 | 1.22 | 0.71 | +137.90% |
| 2021 | 2021-12-31 | 0.51 | — | — |
| 2018 | 2018-12-31 | 0.01 | — | — |
Tempest Therapeutics quarterly debt-to-equity ratio
Q4.18
Q1.19
Q2.19
Q3.19
Q2.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | 9.55 | 8.38 | +711.08% |
| Q4 2025 | 2025-12-31 | 1.22 | 0.42 | +51.98% |
| Q3 2025 | 2025-09-30 | 1.32 | −0.22 | −14.45% |
| Q2 2025 | 2025-06-30 | 0.89 | −0.31 | −25.95% |
| Q1 2025 | 2025-03-31 | 1.18 | 0.19 | +19.31% |
| Q4 2024 | 2024-12-31 | 0.80 | 0.03 | +4.08% |
| Q3 2024 | 2024-09-30 | 1.55 | — | — |
| Q2 2024 | 2024-06-30 | 1.20 | −3.09 | −72.10% |
| Q1 2024 | 2024-03-31 | 0.99 | −0.99 | −50.01% |
| Q4 2023 | 2023-12-31 | 0.77 | −0.45 | −36.79% |
| Q2 2023 | 2023-06-30 | 4.29 | 3.85 | +895.01% |
| Q1 2023 | 2023-03-31 | 1.98 | 1.35 | +217.68% |
| Q4 2022 | 2022-12-31 | 1.22 | 0.71 | +137.90% |
| Q3 2022 | 2022-09-30 | 0.49 | — | — |
| Q2 2022 | 2022-06-30 | 0.43 | 0.03 | +8.66% |
| Q1 2022 | 2022-03-31 | 0.62 | — | — |
| Q4 2021 | 2021-12-31 | 0.51 | — | — |
| Q2 2021 | 2021-06-30 | 0.40 | — | — |
| Q3 2019 | 2019-09-30 | 0.12 | — | — |
| Q2 2019 | 2019-06-30 | 0.07 | — | — |
| Q1 2019 | 2019-03-31 | 0.04 | — | — |
| Q4 2018 | 2018-12-31 | 0.01 | — | — |
Tempest Therapeutics debt-to-equity ratio trends
Between the periods ended 2018-12-31 and 2025-12-31, Tempest Therapeutics's debt-to-equity ratio increased from 0.01 to 1.22, a change of 1.21. The latest reported quarter, Q1 2026, shows 9.55.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Tempest Therapeutics source filings ↗